SCHEMBL19813070

SCHEMBL19813070

NCC1OCCc2cc(F)ccc21

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DRD1 P21728 4/20 0.49
KEAP1 Q14145 1/20 0.47
TAAR1 Q96RJ0 1/20 0.46
HTR1D P28221 11/20 0.45
SLC6A4 P31645 4/20 0.45
HTR2A P28223 3/20 0.43
HTR2B P41595 3/20 0.43
HTR2C P28335 2/20 0.43
HTR1B P28222 7/20 0.42
HTR1A P08908 3/20 0.41
ADRA2A P08913 1/20 0.40
DRD2 P14416 1/20 0.40
ADRA2B P18089 1/20 0.40
ADRA2C P18825 1/20 0.40
DRD4 P21917 1/20 0.40
ADRA1D P25100 1/20 0.40
ADRA1A P35348 1/20 0.40
ADRA1B P35368 1/20 0.40
DRD3 P35462 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19813069 1.00 DRD1 (0.49) DRD1KEAP1TAAR1HTR1DSLC6A4
SCHEMBL7401222 0.81 HTR1D (0.43) DRD1HTR1DSLC6A4HTR2AHTR2B
SCHEMBL7401152 0.81 HTR1D (0.46) DRD1HTR1DSLC6A4HTR2AHTR2B
SCHEMBL20699974 0.81 DRD1 (0.49) DRD1KEAP1TAAR1HTR1DSLC6A4
SCHEMBL19821149 0.81 DRD1 (0.49) DRD1KEAP1TAAR1HTR1DHTR2A
SCHEMBL19812818 0.80 TAAR1 (0.55) TAAR1HTR1DSLC6A4HTR2AHTR2B
SCHEMBL19813091 0.80 TAAR1 (0.55) TAAR1HTR1DSLC6A4HTR2AHTR2B
SCHEMBL19812820 0.80 TAAR1 (0.55) TAAR1HTR1DSLC6A4HTR2AHTR2B
SCHEMBL19824779 0.79 HTR1D (0.42) DRD1TAAR1HTR1DSLC6A4HTR2A
SCHEMBL4502485 0.76 HTR2A (0.53) DRD1KEAP1TAAR1HTR2AHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260035381-A1 COMPOUNDS AND COMPOSITIONS AND USES THEREOF SUMITOMO PHARMA AMERICA, INC. (US) 2026-02-05 US disclosed
US-20240409550-A1 COMPOUNDS AND COMPOSITIONS AND USES THEREOF SUMITOMO PHARMA AMERICA, INC. (US) 2024-12-12 US disclosed
EP-4464317-A2 COMPOUNDS AND COMPOSITIONS AND USES THEREOF Sumitomo Pharma America, Inc. (US) 2024-11-20 EP disclosed
EP-3494119-B1 COMPOUNDS AND COMPOSITIONS AND USES THEREOF SUMITOMO PHARMA AMERICA INC (US) 2024-09-04 EP disclosed
US-11958862-B2 Compounds and compositions and uses thereof SUMITOMO PHARMA AMERICA, INC. (US) 2024-04-16 US disclosed
US-20220340588-A1 COMPOUNDS AND COMPOSITIONS AND USES THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2022-10-27 US disclosed
US-10927124-B2 Compounds and compositions and uses thereof SUNOVION PHARMACEUTICALS INC. (US) 2021-02-23 US disclosed
US-20190308990-A1 COMPOUNDS AND COMPOSITIONS AND USES THEREOF SUNOVION PHARMACEUTICALS INC. 2019-10-10 US disclosed
US-10196403-B2 Compounds and compositions and uses thereof SUNOVION PHARMACEUTICALS INC. (US) 2019-02-05 US disclosed
WO-2018023072-A2 COMPOUNDS AND COMPOSITIONS AND USES THEREOF SUNOVION PHARMACEUTICALS, INC. (US) 2018-02-01 WO disclosed
US-20180030064-A1 COMPOUNDS AND COMPOSITIONS AND USES THEREOF SUMITOMO PHARMA AMERICA, INC. 2018-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10196403-B2 Compounds and compositions and uses thereof CHAT, ACHE, MAOB DRD1 792/4885KEAP1 628/4885TAAR1 893/4885
US-20240409550-A1 COMPOUNDS AND COMPOSITIONS AND USES THEREOF CHAT, ACHE, MAOB DRD1 792/4885KEAP1 628/4885TAAR1 893/4885
US-20260035381-A1 COMPOUNDS AND COMPOSITIONS AND USES THEREOF ADH1C, HTR6, CNR1 DRD1 54/4885KEAP1 433/4885TAAR1 97/4885
US-10927124-B2 Compounds and compositions and uses thereof CHAT, ACHE, MAOB DRD1 792/4885KEAP1 628/4885TAAR1 893/4885
US-11958862-B2 Compounds and compositions and uses thereof CHAT, ACHE, MAOB DRD1 792/4885KEAP1 628/4885TAAR1 893/4885
US-20180030064-A1 COMPOUNDS AND COMPOSITIONS AND USES THEREOF CHAT, ACHE, MAOB DRD1 792/4885KEAP1 628/4885TAAR1 893/4885
US-20220340588-A1 COMPOUNDS AND COMPOSITIONS AND USES THEREOF CHAT, ACHE, MAOB DRD1 792/4885KEAP1 628/4885TAAR1 893/4885
US-20190308990-A1 COMPOUNDS AND COMPOSITIONS AND USES THEREOF CHAT, ACHE, MAOB DRD1 792/4885KEAP1 628/4885TAAR1 893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.